TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement
Researchers in Italy tracked data from more than 7,000 patients who underwent AVR between the ages of 65 and 80. TAVR was associated with a significantly higher long-term risk of mortality.
Heart patients benefit when cardiologists follow a standardized TAVR protocol
Using a standardized approach, including the cusp overlap technique, is associated with improved patient outcomes when implanting Medtronic's self-expanding TAVR valves. Researchers tracked data from more than 600 patients treated all over the world, presenting their findings in JSCAI.
How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR
Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.
Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval
After years of trying to catch up with the competition, Boston Scientific is moving on. The company is no longer seeking approval from the FDA or any other regulatory agencies for these devices, and all global sales have been discontinued.
Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

Edwards shares new data highlighting consistency of its TAVR valves in women, patients with small annuli

Researchers explored five-year data from more than 1,300 TAVR patients treated with a balloon-expandable Sapien 3 valve, sharing their findings at New York Valves 2024: The Structural Heart Summit.

The rapid rise of artificial intelligence (AI) has helped cardiologists, radiologists, nurses and other healthcare providers embrace precision medicine in a way that ensures more heart patients are receiving personalized care.

AI uses imaging results to ID high-risk TAVR patients with speed, accuracy

Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.

M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value.

Osteosarcopenia linked to much higher risk of death after TAVR—CT screening may prove valuable

Osteosarcopenia, an age-related condition associated with deterioration in the muscles and bones, nearly triples a patient’s risk of dying within one year of undergoing TAVR.

alternative approaches for transcatheter aortic valve replacement procedures

Transcaval TAVR a safe, effective alternative for patients with severe AS

Researchers examined data from eight different studies, noting that transcaval TAVR appears to be a "viable alternative" when transfemoral access is not an option. The procedure was linked to an overall success rate of 98.5%.

Newsweek ranked the 50 best heart hospitals in the world

New York Valves, CRF’s newest cardiology conference, makes heart team collaborations a priority

New York Valves: The Structural Heart Summit replaces the Transcatheter Valve Therapy conference CRF hosted for many years. The three-day event will include 12 late-breaking clinical trials focused on TAVR and new treatments for the mitral and tricuspid valves.

doctor examines patient data on their tablet

AVR for moderate AS: New 10-year data highlight clear benefits of TAVR, surgery

New research out of Cleveland Clinic explored long-term outcomes among patients with moderate aortic stenosis who were treated with TAVR, SAVR or clinical surveillance. TAVR and SAVR were both associated with clear improvements compared to surveillance alone.

The EuroPCR 2024 meeting May 14-17 in Paris included four days of late-breaking interventional cardiology science presentations featured 12,100 participants, more than 550 educational sessions and 12 live cases. Photo courtesy of EuroPCR

5 takeaways from late-breaking studies at EuroPCR

The Society for Cardiovascular Angiography and Interventions offers its top five key takeaways from the EuroPCR 2024 meeting last week.

TAVR

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement

Heart patients benefit when cardiologists follow a standardized TAVR protocol

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR

Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards